ArticleVox sanguinis2026
A novel reagent for the screening of Immunoglobulin A-deficient blood donors.
Article in Vox sanguinis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A novel reagent for the screening of Immunoglobulin A-deficient blood donors.Vox sanguinis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesImmunoglobulin A (IgA) deficiency occurs in approximately 1 in 14,000 individuals in Japan. Approximately 32% harbour anti-IgA, most of which are naturally occurring and rarely cause anaphylaxis, although high-titre anti-IgA from alloimmunization can cause severe reactions. A stable supply of IgA-deficient plasma is essential for minimizing this risk. We therefore developed a novel reagent for large-scale identification of IgA-deficient donors. MATERIALS AND
methodsFour mouse monoclonal anti-IgA-producing cell lines were established using the hybridoma method after immunizing mice with IgA protein. Purified antibodies were conjugated to carboxylate-modified polystyrene latex beads for IgA measurement using the latex agglutination method on an automated analyser. Samples with low IgA concentrations were re-tested by enzyme-linked immunosorbent assay (ELISA) for confirmation.
resultsAdoption of a dual antibody assay design achieved a detection limit of 0.4 mg/dL, suitable for high-throughput screening. Screening of 24,977 randomly selected donor samples between February 2022 and April 2023 yielded 4 low IgA cases. IgA deficiency was verified by supplemental ELISA, which was required solely for these four samples. Three of four had IgA levels <0.05 mg/dL, which is the most common threshold for identifying IgA-deficient donors.
conclusionWe have developed a new reagent for detecting IgA deficiency. The assay is automatable and appears useful for large-scale screening of blood donors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.